EuroPCR 2018: Several Studies Add Insight To Best Approach To Stable Coronary Disease, Utility Of FFR
Executive Summary
New clinical data presented at the EuroPCR conference in Paris, including new data from ORBITA, suggest that fractional flow reserve/ instant wave-free ratio-guided percutaneous coronary intervention may produce better long-term outcomes than PCI guided by angiography in terms of mortality, restenosis and stent thrombosis.
You may also be interested in...
AHA 2019: Conservative Approach Works As Well As Intervention For Stable Coronary Disease In ISCHEMIA Trial
The long-awaited results of the ISCHEMIA trial showed that patients with asymptomatic stable coronary disease get no apparent benefit from coronary intervention compared to a more conservative strategy with optimal medical management.
The First Sham-Controlled PCI Trial In Stable Patients
More details about the controversial ORBITA trial.
ACC 2017: Trial Shows FFR-Guidance Can Help Heart Attack Patients Avoid More Revascularizations
Results of the Compare-Acute trial show that STEMI patients benefit from complete revascularization guided by fractional flow reserve measurement, but most of this benefit was driven by the reduction in repeat revascularization. Investigators say more research will be needed to determine if this approach can reduce mortality or other "hard" endpoints.